Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06788509 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

StatusEnrolling by Invitation
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Lead sponsor: Janssen Research & Development, LLC to Janssen Research & Development, LLC Primary endpoints: details revised at 1 of 1 entry · Completion pushed from Oct 30, 2028 to Dec 29, 2028 · Study sites: 38 to 39 · 1 more Show 4 more changesShow less
    • Primary endpoints: details revised at 1 of 1 entry
    • Completion pushed from Oct 30, 2028 to Dec 29, 2028
    • Study sites: 38 to 39
    • Eligibility criteria expanded, about 7 words
  2. Study sites: 36 to 38v20
  3. Trial sites expanded: 33 → 36 locationsv19
  4. Trial sites expanded: 30 → 33 locationsv18
  5. Study sites: 28 to 30v17
  6. Re-verified, no change to tracked fieldsv16
  7. Enrollment increased: 80 → 120 participantsv15
  8. Study sites: 26 to 28 Completion date: Jan 21, 2028 to Oct 30, 2028 · Interventions: JNJ-54179060 (Drug), JNJ-64264681 (Drug), JNJ-64619178 (Drug), JNJ-67856633 (Drug), JNJ-70218902 (Drug), JNJ-74856665 (Drug), JNJ-75348780… to JNJ-54179060 (Drug), JNJ-64264681 (Drug), JNJ-64619178 (Drug), JNJ-67856633 (Drug), JNJ-70218902 (Drug), JNJ-74856665 (Drug), JNJ-75348780…v14 Show 2 more changesShow less
    • Completion date: Jan 21, 2028 to Oct 30, 2028
    • Interventions: JNJ-54179060 (Drug), JNJ-64264681 (Drug), JNJ-64619178 (Drug), JNJ-67856633 (Drug), JNJ-70218902 (Drug), JNJ-74856665 (Drug), JNJ-75348780… to JNJ-54179060 (Drug), JNJ-64264681 (Drug), JNJ-64619178 (Drug), JNJ-67856633 (Drug), JNJ-70218902 (Drug), JNJ-74856665 (Drug), JNJ-75348780…
  9. Study sites: 23 to 26v13
  10. Re-verified, no change to tracked fieldsv12
  11. Study sites: 22 to 23v11
  12. Re-verified, no change to tracked fieldsv10
  13. Study sites: 21 to 22v9
  14. Study sites: 17 to 21v8
  15. Study sites: 13 to 17v7
  16. Re-verified, no change to tracked fieldsv6
  17. Study sites: 11 to 13v5
  18. Study sites: 9 to 11v4
  19. Re-verified, no change to tracked fieldsv3
  20. Study sites: 4 to 9v2
  21. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Johnson & Johnson
289 trials monitored
See 17 trials at risk
Leukemia
2,566 trials monitored
See 143 trials at risk
Prostate Cancer
2,487 trials monitored
See 160 trials at risk
Non-Hodgkin Lymphoma
1,517 trials monitored
See 84 trials at risk
and 3 more diseases
The purpose of this study is to collect long-term safety data in participants with cancers including acute myeloid leukemia, non-Hodgkin lymphoma, myelodysplastic syndrome, chronic lymphocytic leukemia (type of cancer of the blood and bone marrow in which the bone marrow makes a large number of abnormal blood cells) and advanced solid tumors and metastatic castration-resistant prostate cancer (mCRPC).
Trial Details
NCT Number NCT06788509
Lead Sponsor Janssen Research & Development, LLC
Conditions Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Neoplasms, Solid Tumor, Adult, Prostatic Neoplasms, Castration-Resistant
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov